On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
TuesdayFeb 18, 2020 2:06 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Strikes Licensing Deal with Cannadips CBD

British Columbia-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently entered a definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips CBD. An article discussing the company reads, “The agreement announced recently provides Cannadips CBD with exclusive access rights to Lexaria’s technology for the U.S. market for 10 years, granting the ‘Original Smokeless CBD Dip Brand’ Lexaria’s fast-acting, high-absorption technology with options to expand the license to Europe, Mexico, and Canada and to renew the license for an additional five years (http://ibn.fm/8hoPO). . . . ‘This combination of superior science from Lexaria and a unique and strong branded proposition that…

Continue Reading

FridayFeb 14, 2020 11:54 am

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Demonstrates Applicability of Drug Delivery Platform Through Relationships with Fortune 500 Leaders

Lexaria’s DehydraTECH(TM) drug delivery platform a feasible and healthier alternative to other delivery methods The fast-acting, high absorption technology improves dipping experience and consumer satisfaction Company expects to more than double its 2019 revenue this year, will pursue a new capital markets strategy to qualify for listing on a nationally recognized U.S. exchange Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms and one of the few companies active in the field of cannabis to have developed formal relationships with Fortune 500 industry leaders, is experiencing strong demand from many companies requesting pre-processed DehydraTECH(TM)-enhanced bulk powders.…

Continue Reading

ThursdayFeb 13, 2020 12:05 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Cannabis Oral Pouch & Dip Niche through Lucrative New Partnership

Lexaria’s fast-acting, high absorption technology will improve dipping experience and consumer satisfaction Partnership will enable Lexaria’s to provide its DehydraTECH(TM) drug delivery platform to Cannadips Cannnabis products in California and nationwide Cannadips to open one-of-a-kind cannabis oral pouch and dip research facility Global innovators in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will provide its patented DehydraTECH(TM) technology to Cannadips Cannabis for use on the latter’s market in California and nationwide according to a new definitive agreement. Currently, Cannadips Cannabis Tins are sold in California. Each tin contains 15 pouches with 10 mg of tetrahydrocannabinol each, no…

Continue Reading

ThursdayFeb 13, 2020 10:09 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) DehydraTECH(TM)-Enabled CBD Infused Powders Available for Sale Across the US

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that its DehydraTECH(TM)-enabled CBD infused powders are now available for sale across the U.S. to businesses wanting to produce topicals and edibles with clinically proven performance for increased consumer satisfaction and improved stability. Consumers of both CBD/hemp and cannabis have recently become concerned about the potency and safety of the oil extract products they are purchasing. Lexaria's patented DehydraTECH(TM) technology and powder processing methodology, similar to a pasteurization technique in some ways, helps to not only preserve cannabinoid potency but also to reduce or eliminate…

Continue Reading

ThursdayFeb 06, 2020 3:09 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Providing Alternative to Inhalation via Patented Oral Drug-Delivery Technology

British Columbia-based, biodelivery technology developer Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is committed to the idea that better alternative methods for drug delivery exist than inhalation. A recent article discussing the company reads, “Swallowed medications have historically been slower to provide effective action than inhaled ones, leading substance users looking for a quick fix to lean toward the latter. But the deleterious and deadly consequences of smoking tobacco products have been publicly acknowledged for decades, though hardly stemming the tide of nicotine addiction as one generation succeeds another. . . . The continued preference for the rapid delivery of inhaled…

Continue Reading

WednesdayJan 29, 2020 1:52 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Technology Accelerates Delivery of CBD into Bloodstream

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) 2.0 version of its patented DehydraTECH(TM) oral drug-delivery technology has demonstrated its power to deliver more cannabidiol (“CBD”) into the bloodstream than generic industry-control formulations (http://ibn.fm/Utl7A). An article discussing the company reads, “The company’s 2.0 technology is specifically being developed for effectiveness in helping to deliver its drug payload across the blood-brain barrier, a natural biological system of blood vessels and endothelial cells that bar most drugs from accessing the brain’s central-nervous-system hierarchy. The ability to effectively deliver drugs to the brain is of keen interest to developers of drugs designed to beneficially target…

Continue Reading

WednesdayJan 22, 2020 12:35 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Inks Licensing Deal with Smokeless Cannadips CBD Product Maker

Lexaria Bioscience is a company dedicated to developing effective oral ingestion methods for drug substances that rival the rapid-delivery qualities of more health-dangerous inhaled-drug products. Inhalation is a particularly popular method of using tobacco and cannabis products, despite government warnings about the scientifically established dangers of doing so Lexaria has been boosting its profile and revenue potential through licensing agreements with other companies Lexaria recently announced a licensing agreement with Cannadips CBD-maker The Boldt Runners Corporation The agreement grants Cannadips CBD use of Lexaria’s DehydraTECH IP to improve the speed of its effectiveness and to combat the throat irritation that…

Continue Reading

WednesdayJan 22, 2020 10:00 am

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Provide Patented DehydraTECH(TM) to Cannadips’ Cannabis Products in California and Across the US

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has reached a new definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips' cannabis products, both in its current California market and across the United States. According to the update, Lexaria's DehydraTECH fast-acting, high-absorption technology is perfectly suited to improve consumer satisfaction and the dipping experience. Terpene-rich multi spectrum oils are base ingredients of Cannadips THC, and DehydraTECH is able to reduce throat irritation normally associated with some terpenes. Inferior products utilize less efficacious cannabis isolate without terpenes that lack the entourage…

Continue Reading

ThursdayJan 16, 2020 1:01 pm

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Expects Sustainable Revenue Growth, Plans New Capital Markets Strategy in 2020

Growing interest in the company’s innovative DehydraTECH™ drug delivery platform from large global corporations Lexaria’s strategy to be listed on a nationally recognized U.S. exchange will help the company access a significantly larger audience of investors Lexaria has 16 patents with another 60 pending worldwide and is the only company to hold a patent for improved delivery of all non-psychoactive cannabinoids Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, has achieved virtually everything it set out to do in 2019 and has even bigger plans for 2020 that include achieving higher revenue and being listed…

Continue Reading

WednesdayJan 15, 2020 1:29 pm

Concerns About Vape Addiction, Injury Provide Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) with Opportunity

Lexaria Bioscience continues to advance the effectiveness of its proprietary DehydraTECH technology, a formulation that teams with drug substances such as nicotine and cannabidiol to quickly carry those drugs into a user’s blood stream Recent concerns about the safety of vape products and ongoing concerns about the safety of tobacco are opening doors to Lexaria’s edible technology Newly legalized cannabis-infused edibles began hitting store shelves nationwide in Canada last month, presenting Lexaria with new potential licensing outlets for its increasingly effective products If 2019 was the year when vape users discovered the potential perils of using untested off-brand products, 2020…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered